Cancer Treatment Reviews

Article	Citations
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon	188
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer	179
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	170
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer	161
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis	141
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms	127
Acknowledgement to Reviewers 2021	120
Editorial Board	117
Editorial Board	105
Editorial Board	103
Editorial Board	101
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review	86
Editorial Board	81
Editorial Board	80
Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)	76
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations	74
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review	73
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review	70
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications	69
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	65
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis	60
Editorial Board	60
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma	59
The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review	57
PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives	57

Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches	55
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies	53
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines	52
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	51
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?	51
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	51
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	49
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions	49
Current state of play for HPV-positive oropharyngeal cancers	48
NTRK gene fusion testing and management in lung cancer	48
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	45
Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis	45
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers	45
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review	45
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice	44
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy	43
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants	42
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon	42
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma	42
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges	41
Systemic therapy for older patients with early breast cancer	39
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification	39
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas	39
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee	38
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	37
Cabozantinib: An evolving therapy for hepatocellular carcinoma	37
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing	36
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies	36
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	36
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	36
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group	36
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer	36
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	35
Beyond HER2: Targeting the ErbB receptor family in breast cancer	35
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review	34
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes	34
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	33
Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review	32
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer	32
Precision medicine for multiple myeloma: The case for translocation (11;14)	32
Neurological complications of cancer immunotherapy	31
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers	31
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?	31
Local control strategies for management of NSCLC with oligoprogressive disease	31
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	31
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer	30
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies	30
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?	30
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?	30
Systematic review of fetal and placental metastases among pregnant patients with cancer	30

Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors	29
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?	29
Microsatellite instability in Gastric Cancer: Between lights and shadows	29
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes	29
Treatment landscape of metastatic pancreatic cancer	29
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie	28
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review	28
Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians	28
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?	27
Editorial Board	27
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review	25
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	25
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]	25
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II	25
Engineering strategies to optimise adoptive cell therapy in ovarian cancer	25
Optimizing care in early phase cancer trials: The role of palliative care	24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project	24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives	24
Corrigendum to “Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis” [Cancer Treatm. Rev. 93 (2021) 102141]	23
If it’s a target, it’s a pan-cancer target: Tissue is not the issue	23
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force	23
Molecular aspects of brain metastases in breast cancer	23
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration	22
Locally advanced and metastatic endometrial cancer: Current and emerging therapies	22
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer	22
Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review	21
Clinical trial designs for evaluating and exploiting cancer evolution	21
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news	21
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies	21
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	20
Editorial Board	20
Compliance to chemoradiation in squamous cell carcinoma of the anus	20
Editorial Board	20
Editorial Board	20
Editorial Board	20
Impact of molecular profiling on the management of patients with myelofibrosis	19
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I	19
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)	19
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features	19
Editorial Board	19
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer	19
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis	19
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer	18
First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?	18
Accelerating drug development in breast cancer: New frontiers for ER inhibition	18
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis	18
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence	18
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations	18
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer	18
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis	17
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer	17
Emerging antibody-based therapies for the treatment of acute myeloid leukemia	17
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis	17
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond	17
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	17
Rethinking breast cancer follow-up based on individual risk and recurrence management	17
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis	17
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis	16
Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis	16
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors	16
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives	16
Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: A systematic review and meta-analysis	16
Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy	16
Hormone receptor-positive early breast cancer in young women: A comprehensive review	16
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies	16
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	16
Oncological risks associated with the planned watch-and-wait strategy using total neoadjuvant treatment for rectal cancer: A narrative review	16
Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review	15
Pharmacotherapy for leptomeningeal disease in breast cancer	15
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis	15
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development	15
The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment	15
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing	15
Optimizing lung cancer radiation therapy: A systematic review of multifactorial risk assessment for radiation-induced lung toxicity	15
Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives	15
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives	15
Evolving immunotherapeutic solutions for triple-negative breast carcinoma	15
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives	14
Antibody based therapies in Hodgkin lymphoma	14
The current clinical landscape of personalized cancer vaccines	14

Review: Targeting EZH2 in neuroblastoma	14
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	14
Strategies for improving detection of circulating tumor DNA using next generation sequencing	14
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	13
Editorial Board	13
Editorial Board	13
Editorial Board	13
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	13
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature	13
Editorial Board	13
Editorial Board	13
Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into ac	13
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	13
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges	13
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature	13
Editorial Board	13
Editorial Board	13
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment	12
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications	12
Therapeutic strategies and landscape of metaplastic breast cancer	12
Editorial Board	12
Targeting NaPi2b in ovarian cancer	12
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	12
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis	12
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy	12
Response to ‘considerations regarding a network meta-analysis of targeted therapies for BRAF mutant unresectable or metastatic melanoma’	12
Emerging therapies for rare cutaneous cancers: A systematic review	12
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era	12
Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future	11
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	11
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies	11
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives	11
Corrigendum to “Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications” [Cancer Treat. Rev. 130 (2024) 102816]	11
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis	10
Immunotherapy in advanced anal cancer: Is the beginning of a new era?	10
HER2 targeted therapy in colorectal cancer: New horizons	10
Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review	10
Uncertainties and controversies in axillary management of patients with breast cancer	10
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors	9
The association between guideline adherence, age and overall survival among women with non-metastatic breast cancer: A systematic review	9
NRAS mutant melanoma: Towards better therapies	9
Roadmap to cure multiple myeloma	9
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases	9
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis	9
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma	9
The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives	9
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review	9
Editorial Board	8
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	8
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review	8
Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis	8
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target	8
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review	8
SELNET clinical practice guidelines for soft tissue sarcoma and GIST	8
Bridging gaps in cancer cachexia Care: Current insights and future perspectives	8
The promise of bispecific antibodies: Clinical applications and challenges	8
Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer	8
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies	8
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”	8
Low grade serous ovarian cancer – A rare disease with increasing therapeutic options	8
Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence	8
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	8
Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives	8
Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: A systematic review	8
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review	8
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer	8
Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer	7
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer	7
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality	7
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis – A review	7
Salivary gland carcinoma: Towards a more personalised approach	7
The evolving landscape of antibody-drug conjugates in gynecologic cancers	7
Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review	7
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	7
Novel targets for immune-checkpoint inhibition in cancer	7
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies	7
Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials	7
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review	7
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies	7
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision	7
Immunotherapy-based combinations in metastatic NSCLC	7
Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?	6
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review	6
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of	6
Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies	6
Long road towards effective HER3 targeting in breast cancer	6
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?	6
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments	6
Treatment of venous thromboembolism in cancer patients: The dark side of the moon	6
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma	6
Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review	6
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	6
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review	6
Overview of BH3 mimetics in ovarian cancer	6